Servotronics Deal Rewrite Ignites Shareholder Value
Servotronics, Inc. (NYSE:SVT) announced that the company, along with TransDigm Group Incorporated (NYSE:TDG), has made adjustments to the Agreement and Plan of Merger, raising the tender offer price to $47 per share from $38 per share in cash for all outstanding shares. This decision was taken soon after the company received an unsolicited takeover proposal from a third party. While the external offer is not the one that can be prioritized, it signals enhanced shareholder value.
A close-up of a scientist's hands manipulating a high-powered microscope to view cells.
The servo-control components provider, encompassing manufacturing capabilities for aircraft, jet engines, and missiles, signifies a specialized acquisition prey in the aerospace supply chain. Although the transaction still faces the regulatory approval process and closing conditions, among other challenges, the acquisition perfectly syncs with TransDigm's portfolio expansion plans.
This is a major factor in the current stock movement, with investors reacting positively to this update, translating to a stock rise. Now that the news is out, investors are staying tuned for the next move, hoping the tender offer delivers even more attractive returns. SVT has surged by nearly 328% since the start of 2025.
While we acknowledge the potential of SVT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SVT and that has 100x upside potential, check out our report about the
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure. None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
Billionaire Stanley Druckenmiller Owns $175 Million of This Brilliant Dividend Growth Stock
Philip Morris International is one of the largest positions in Stan Druckenmiller's portfolio. The stock has soared because of its leading position in disruptive nicotine categories. The stock can produce plenty of dividend growth for the rest of this decade. 10 stocks we like better than Philip Morris International › It can pay to follow billionaire fund manager Stanley Druckenmiller, who has put up phenomenal market-beating returns for decades. One of the largest positions in his Duquesne Family Office is Philip Morris International (NYSE: PM). He owns $175 million worth of the stock, first purchased in the second quarter of 2024. Since then, shares have posted a total return of more than 100% as investors have gotten excited about the company's growth with new nicotine brands that are replacing cigarettes. Here's the brilliance behind Philip Morris' strategy, and why this is the perfect dividend growth stock over the next 10 years. Spun out as an independent company almost two decades ago, Philip Morris International is one of the leading tobacco companies that sells outside of the United States, while Altria Group sells its brands domestically. One benefit of owning Philip Morris International is the international diversification it can provide for your portfolio. Even though the company reports in U.S. dollars, the revenue it collects is generally outside the United States, which can help investors when the dollar is getting devalued versus foreign currencies, as is happening today. The stock has soared mainly because of the major investments the company made beyond cigarettes that are now bearing fruit. It has the leading nicotine pouch brand called Zyn, which is growing like wildfire in the United States, and with incredible profit margins. The brand has gone from virtually nothing 10 years ago to selling more than 200 million cans a quarter in the country. More globally, the Iqos heat-not-burn device brand is the leader in the category that is popular in Europe and Japan, driving tons of new revenue and earnings for Philip Morris International. Overall, 42% of the company's revenue now comes from its smoke-free business, driving overall revenue to $38.4 billion over the last 12 months. Dividends are the way that Philip Morris returns capital to shareholders. Its dividend yield is much lower than a year ago at 3%, but it still offers a solid yield for shareholders. One big factor in this dividend consistency is the steady cash flow produced by the legacy cigarette business. Usage for cigarettes is slowly declining in the markets in which it operates, but the company is in a much better position outside of the United States because of its exposure to countries with growing populations. It also has the leading brands that consumers of nicotine are switching to buy. Today, Philip Morris pays a dividend per share of $5.35. This will be funded by its free cash flow per share, currently at $6.55. No cash flow, no dividends. It's that simple at the end of the day. Free cash flow is actually depressed right now because of the large manufacturing build-out for nicotine pouches and heat-not-burn growth. Over the next five years, investors should see an inflection in free cash flow per share up to $10 or higher. In turn, this gives the company plenty of room to grow its dividend-per-share payout, which will boost the dividend yield as long as the stock price doesn't go up. Around 10% dividend growth for the next five years will put the stock's dividend-per-share payout at $8.61, which is well below what the company can generate in free cash flow. This gives the company an easy path to keep growing its dividend payout for shareholders. Even though the stock is up 100% in the last 12 months or so, Philip Morris International stock may still be a solid buy for investors today. Don't expect 100% returns every year, but the math works out that this stock is still cheaper than most you can buy today. It has a forward price-to-earnings ratio (P/E) of 24, which is not overly expensive for a consistent earnings grower. The dividend yield is well above the stock market average, with plenty of room to grow this yield in the years to come. Philip Morris has the dominant position in the growing trend of nicotine use without tobacco, which will make it a market share taker versus competitors. Put it together, and Philip Morris International is a great stock to buy and hold for the long haul. No wonder Druckenmiller has it as one of the largest positions in his portfolio. Before you buy stock in Philip Morris International, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Philip Morris International wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Brett Schafer has no position in any of the stocks mentioned. The Motley Fool recommends Philip Morris International. The Motley Fool has a disclosure policy. Billionaire Stanley Druckenmiller Owns $175 Million of This Brilliant Dividend Growth Stock was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
$4.8M for unfinished work: Attorney General pledges accountability for Lexington Blue roofing
LEXINGTON, Ky. (FOX 56) — A court order has mandated the roofing company, Lexington Blue, to immediately cease operations. An investigation into the company was opened by Attorney General Russell Coleman after learning that the company allegedly accepted $4.8 million for more than 300 projects, and the majority went unfinished. RELATED | Kentucky roofing company facing lawsuit after allegedly going out of business with unfinished paid projects lined up More than 70 of its clients have filed complaints, the attorney general's office said. According to the Lexington Blue website, the company had to close due to 'extraordinary and unforeseen challenges, including unrelenting internal disruptions and attempts to sabotage our operations, including, but not limited to, negative press and reviews.' 'We are constantly on guard against predatory organizations that try to take advantage of Kentuckians, and we will hold these bad actors accountable,' Coleman said. 'We're sending a strong message to scammers that they will face serious consequences when they operate within our Commonwealth.' $4.8M for unfinished work: Attorney General pledges accountability for Lexington Blue roofing Kentucky man killed in tornado remembered for his hard work, kind heart: 'He wanted to give back' Study shows Kentucky among the poorest states The court order will prevent Lexington Blue and its operators from transferring or liquidating assets and freeze the defendant's corporate and personal accounts. Coleman encourages anyone affected by the company to contact the office here or by calling (888)432-9257. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
2025 ASCO Presentation: Innovent Biologics Announces Updated Data of IBI354 (Novel anti-HER2 ADC) From the Phase 1/2 Clinical Study in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors
SAN FRANCISCO and SUZHOU, China, June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, updated the clinical data of IBI354 (HER2 monoclonal antibody-camptothecin derivative conjugate) in advanced solid tumors at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. IBI354 has demonstrated promising anti-tumor efficacy and favorable safety profiles across multiple solid tumors. It not only holds potential to deliver a new generation of ADC therapies characterized by "high potency and low-toxicity" for tumor types such as ovarian cancer and breast cancer, but also validates the advantages of Innovent's ADC technology platform. The results of IBI354 lays the foundation for the subsequent development of Innovent's next-generation of bispecific ADCs and dual-payload ADCs, marking a milestone in Innovent's next-generation "IO+ADC" oncology development strategy. The data presented is from a Phase 1/2 clinical study (NCT05636215) aimed at evaluating the safety, tolerability, and preliminary efficacy of IBI354 in participants with advanced solid tumors. As of March 24, 2025, a total of 368 participants with advanced solid tumors were enrolled and received different doses of IBI354 monotherapy, the median follow-up duration was 11.5 months (range: 0.7-19.6), the median treatment duration was 27.0 weeks (range: 3.1-81.3) and 74 (20.1%) pts were still on treatment. The tumor types including 178 with breast cancer, 92 with ovarian cancer, 38 with colorectal cancer, and 60 with other tumors. IBI354 monotherapy demonstrated excellent safety profile The dosage was escalated to 18mg/kg, with no DLT events observed. The most common treatment-related adverse events (TRAEs) were anemia, nausea, and white blood cell count decreased. The incidence of interstitial lung disease (ILD) was only 1.9%, all were grade 1-2. Overall, 27.4% of patients experienced TRAEs ≥ grade 3, 17.7% experienced TRAEs leading to dose interruption, 2.7% experienced TRAEs leading to dose reduction and 1.6% experienced TRAEs leading to discontinuation, with no TRAEs leading to death. IBI354 monotherapy showed promising efficacy signals in multiple tumor types In HER2-positive breast cancer cohort (n= 88, treated at 6~15mg/kg, the median prior treatment lines was 4), the confirmed objective response rate (ORR) and the disease control rate (DCR) were 59.1% and 90.9%, respectively. In 9 mg/kg Q3W subgroup (n=29), the ORR and the DCR were 72.4% and 89.7%, respectively. The median progression-free survival (PFS) was 14.1 months (95% CI: 8.3-not calculable [NC]) with events of 48.3%. The median overall survival (OS) was immature with events of 3.4%. In ovarian cancer cohort (n=92, treated at 2~12mg/kg, the median prior treatment lines was 3), the cORR was 41.2% and the DCR was 82.0%. In the 12mg/kg Q3W subgroup (n=40), the cORR reached 55.0% and the DCR was 90.0%. In participants with HER2 1+ (n=27), the ORR reached 55.6% and the DCR was 88.9%. As of the data cutoff date, the median follow-up time was 11.9 months, and the median PFS was 7.1 months (95% CI: 5.2−10.8) in 12mg/kg Q3W dose group. The median OS was not mature with events in 14 (34.1%) pts and a 12-month OS rate of 63.9% (95% CI: 45.0−77.8). Professor Qi Zhou, Chief Physician at the Gynecologic Oncology Center of Chongqing University Affiliated Cancer Hospital and the Principal Investigator of the gynecologic oncology cohort study, stated, "The treatment of platinum-resistant recurrent ovarian cancer is difficult and the prognosis is poor, threatening the life and health of women. Extending PFS and OS in platinum-resistant recurrent ovarian cancer patients remains a clinical challenge for gynecological oncologists. ADC drugs provide a new direction for overcoming resistance mechanisms by precisely delivering cytotoxic agents. HER2, as a validated solid tumor target, has made breakthroughs in breast and gastric cancer fields, while the novel ADC drug IBI354 shows broad-spectrum antitumor activity through unique design in HER2 low-expression (IHC 1+) platinum-resistant ovarian cancer. In the Phase 1 study with a dose of 12mg/kg Q3W, IBI354 demonstrated an ORR of 55.0% and DCR of 90.0%, with a median PFS reaching 7.1 months. The safety profile was very good without common severe interstitial lung disease or ocular toxicity seen in other ADCs. These results significantly outperform traditional chemotherapy regimens, suggesting its potential breakthrough efficacy in the platinum-resistant population. The Phase 3 study of IBI354 in platinum-resistant ovarian cancer (HeriCare-Ovarian01) has been initiated, and I am looking forward to the results, as well as the further validation of the long-term benefits for patients receiving IBI354." Doctor Charlotte Rose Lemech from Scientia Clinical Research Ltd, Australia, stated: "Breast cancer is one of the most common malignant tumors among women globally and remains a leading cause of cancer-related deaths. The amplification or overexpression of HER2 (human epidermal growth factor receptor 2) is recognized as a key driver in the development, progression, and metastasis of breast cancer, with approximately 15%-20% of breast cancer patients exhibiting HER2 overexpression. ADCs have become the new standard treatment for later line HER2 positive breast cancer. In this Phase 1 study, IBI354 has demonstrated encouraging efficacy and safety data, achieving high ORR and DCR especially in 9 mg/kg Q3W subgroup. Long term survival was also achieved with the median PFS of 14.1 months. IBI354 also differentiates itself from other HER2 targeted therapies with its safety profile. The incidence of interstitial lung disease was extremely low and most of the hematological toxicity and gastrointestinal adverse events were mild to moderate and can be effectively managed with standard supportive care. This favorable safety profile enhances the clinical application potential of IBI354 and we look forward to IBI354 achieving more breakthroughs in the field of breast cancer treatment." Dr. Hui Zhou, Senior Vice President of Innovent, stated: "With the rapid development of ADC drugs in the field of tumor treatment, Innovent is steadily advancing its strategic layout in the ADC field. At this year's ASCO conference, we update the safety and efficacy data of IBI354 across various advanced solid tumors. These clinical results not only confirm the potential therapeutic value of IBI354 but also demonstrating Innovent's innovative strength and technological advantages in ADC drug development. The phase 3 study of IBI354 in platinum-resistant ovarian cancer has been initiated, and more clinical studies are also planned. We will continue to invest in next-generation ADC molecules, aiming to address unmet clinical needs and bring patients with more effective and safer treatment options." About IBI354 (Anti-HER2 Antibody-Camptothecin Derivative Conjugate) IBI354 is an innovative HER2-targeted antibody–camptocinin derivative conjugate developed by Innovent's proprietary SoloTx ADC platform. With a drug-to-antibody ratio (DAR) of 8, IBI354 delivers a high payload of effective drugs to tumors. The highly hydrophilic linker design contributes to its excellent biophysical and pharmacokinetic (PK) properties, while the hydrophobic payload enhances its bystander effect, targeting adjacent antigen-low or negative tumor cells. IBI354 exhibits extremely low exposure of free toxin in circulation and has an ideal safety profile based on pre-clinical and clinical studies. IBI354 has demonstrated remarkable anti-tumor activity in various tumor-bearing mice models, particularly in those resistant to HER2-targeted therapies and in metastatic tumors. Innovent Biologics is conducting clinical studies to assess the efficacy and safety of IBI354 for multiple advanced solid tumors. About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Statement: （1）Innovent does not recommend the use of any unapproved drug (s)/indication (s). （2）Ramucirumab (Cyramza®) and Selpercatinib (Retsevmo®) and Pirtobrutinib (Jaypirca®) were developed by Eli Lilly and Company. Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. View original content: SOURCE Innovent Biologics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
